Ann recently posted about massively parallel genomic sequencing using maternal blood as a
screening test for Down syndrome. In it, she described a recently published, multi-center clinical study that validated this molecular test in just over 1,600 women. The test detected 98.6% of the Down syndrome fetuses and had a false-positive rate of 0.2%. Notably, this performance is considerably better than current biochemical marker Down syndrome screening tests.
- It’s expensive and available from only one company. The Sequenom Center for Molecular Medicine, located in Grand Rapids, MI, developed the test and is currently the only place in the US that can do it. It's marketed as the MaterniT21 test and costs $1,900 for the uninsured and ~$235 for those with insurance. Biochemical screening tests cost much less.
- After the blood sample arrives in the lab, test results are available in about 10 days. Results for biochemical screening tests take about 1 day.
- The test can only be performed in singleton pregnancies (not twins, triplets, etc). Biochemical screening tests work best in singleton pregnancies, too, although risks can be estimated from a twin pregnancy.
- The test fails to work in about 2% of cases, usually as a result of there not being enough fetal DNA detected in the mother's blood. This is more likely to be the case in overweight women who have a higher blood volume which dilutes the amount of the fetal DNA. The concentrations of the markers used in biochemical screening tests are also effected by maternal weight but there are effective ways to account for that so that the final result is not affected.
- The test is only validated for the detection of Down syndrome and not other fetal aneuploidies such as trisomy 18 or trisomy 13. The test does have the capability of detecting these disorders and, if they are detected, will be reported. However, because the test has not been thoroughly investigated for detecting T18 or T13 a negative result doesn't rule out their presence. Biochemical screening tests can detect these disorders although the detection rates are lower than they are for Down syndrome.
- The test does not detect open neural tube defects (e.g. spinal bifida) that are usually screened for using biochemical screening tests.
I have no doubt that as the technology required to do massively parallel genomic sequencing becomes less expensive, tests like the MaterniT21 will become more affordable and mainstream. Most of the limitations I described above will also be addressed with time and technological improvements. As Ann indicated, this is the dawn of a new era in screening for fetal disorders.